Washington Department of Health Boyer Letter Re Controlled Substance Medications 2010
Download original document:
Document text
Document text
This text is machine-read, and may contain errors. Check the original document to verify accuracy.
STATE OF WASHINGTON DEPARTMENT OF HEALTH Olympia, Washington 98504 May 13, 2010 All Pharmacies All licensed Residential Treatment Facilities RE: Controlled Substance Medications I am writing to address concerns regarding federal requirements for management, use and control of controlled substances in residential treatment facilities. Current state and federal regulations require that pharmacies providing pharmaceutical services to residential treatment facilities provide only patient specific medications. The only exception is a pharmacy may utilize an automated drug distribution device (for example Pyxis) in the facility with staff credentialed to administer medications. A pharmacy is responsible to obtain a Board of Pharmacy approval (WAC 246-872) for all automated drug distribution devices. Additionally a pharmacy then must obtain a DEA registration for that specific machine in that facility location when controlled substances are involved. The Board of Pharmacy recommends residential treatment facilities pursue methods for providing patient specific medications. 1. Use of a 24 hour retail or long term care pharmacy 2. Use of a 24 hour hospital pharmacy For all other controlled substances, an automated drug distribution device approved by the board and DEA is the only method. These methods need to be in place by December 31, 2010. After December 31, department inspectors will require plans of corrections for facilities failing to meet this requirement. Please contact Tim Fuller, board pharmacist consultant, for the approval process for automated drug distribution devices. Tim can be reached at tim.fuller@doh.wa.gov. Sincerely, Susan Teil Boyer, RPh, Executive Director Washington State Board of Pharmacy, and Clinical Facilities Office of Health Professions Cc: Grant Chester, Chief Investigator Ruth Carter, DEA Regional Supervisor Barbara Runyon, RN, Nurse Consultant Tim Fuller, Pharmacist Consultant